SAB Biotherapeutics, Inc. (SABS)
SABS moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How SABS actually reacts to news — the realized, point-in-time move the market made, measured across 256 labeled events over the last three years with zero look-ahead.
SABS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 206 |
| 30-min | 0.00% | 48% | 228 |
| 60-min | 0.00% | 45% | 238 |
| to close | 0.00% | 42% | 253 |
| Middle 50% of SABS reactions | -1.07% to +1.73% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 256 |
Half of all SAB Biotherapeutics, Inc. news events land between -1.07% and +1.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SABS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.13% | 50% | +1.22% |
| Coverage initiations | 32 | +0.57% | 63% | 0.00% |
| Rating reiterations | 46 | +0.55% | 67% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SABS ranks against every other measured name →
That’s how SABS usually reacts — get an email when it moves on news →Email me when SABS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SABS's baseline. Nothing else.
Recent SABS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| SAB BIO to Participate in Chardan 10th Annual Healthcare Conference | Press release | GlobeNewswire | -1.51% | -5.68% | |
| Form 8-K SAB Biotherapeutics, For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | -5.63% | |
| SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes | Press release | GlobeNewswire | -0.35% | -5.63% | |
| SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress | Press release | GlobeNewswire | -0.95% | -2.86% | |
| SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes | Press release | GlobeNewswire | +0.00% | +2.34% | |
| SAB BIO to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.37% | +1.37% | |
| Form 10-Q SAB Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.27% | +2.39% | |
| SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights | Press release | GlobeNewswire | -0.27% | +2.39% | |
| SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET | Press release | GlobeNewswire | +2.29% | +2.01% | |
| Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes | Press release | GlobeNewswire | -6.91% | -0.26% | |
| Form 8-K SAB Biotherapeutics, For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -6.91% | -0.26% | |
| Form 8-K SAB Biotherapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | -1.75% | |
| SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting | Press release | GlobeNewswire | -0.28% | +1.12% | |
| Form 10-Q SAB Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.63% | -4.74% | |
| SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -2.63% | -4.74% | |
| SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET | Press release | GlobeNewswire | -0.55% | +0.55% | |
| Form 8-K SAB Biotherapeutics, For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | +0.55% | |
| Form DEF 14A SAB Biotherapeutics, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +2.02% | -6.72% | |
| Form 8-K SAB Biotherapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +3.64% | |
| SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 | Press release | GlobeNewswire | +0.26% | +3.64% | |
| SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress | Press release | GlobeNewswire | -1.04% | +4.92% | |
| Form S-8 SAB Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.78% | |
| Form 8-K SAB Biotherapeutics, For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | +2.17% | +2.44% | |
| SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +1.07% | +0.27% | |
| SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -2.00% | -7.50% | |
| SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -2.00% | -7.50% | |
| Form 8-K SAB Biotherapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | +1.24% | |
| SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes | Press release | GlobeNewswire | +0.25% | +1.24% | |
| Form 10-K SAB Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.25% | +1.24% | |
| SAB BIO Reports Full Year 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | +0.25% | +1.24% | |
| SAB BIO to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.16% | +3.30% | |
| SAB BIO to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.22% | -6.21% | |
| Form 8-K SAB Biotherapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | +5.91% | |
| Form EFFECT SAB Biotherapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -3.68% | -5.39% | |
| Form 8-K SAB Biotherapeutics, For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +2.85% | |
| SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director | Press release | GlobeNewswire | -0.26% | +2.85% | |
| SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.36% | -3.47% | |
| Form S-3 SAB Biotherapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.56% | +5.31% | |
| Form 8-K SAB Biotherapeutics, For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.72% | |
| First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D | Press release | GlobeNewswire | -0.48% | -0.75% | |
| SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D | Press release | GlobeNewswire | -0.50% | -0.75% | |
| Form S-8 SAB Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.75% | -0.50% | |
| SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management | Press release | GlobeNewswire | -0.50% | -11.25% | |
| Form 10-Q SAB Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.31% | +6.93% | |
| SAB BIO to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.02% | +3.50% | |
| SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 | Press release | GlobeNewswire | +3.02% | +3.50% | |
| Form EFFECT SAB Biotherapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -1.00% | -0.50% | |
| Form 8-K SAB Biotherapeutics, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | -0.50% | |
| Form 8-K SAB Biotherapeutics, For: Sep 26 | SEC filing · Form 8-K | SEC EDGAR | +1.76% | -4.41% | |
| Form S-3/A SAB Biotherapeutics, | SEC filing · Form S-3 | SEC EDGAR | -2.02% | -8.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SABS section they belong to.
Where else SABS is measured.
SABS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is SAB Biotherapeutics, Inc.'s median reaction calculated?
Every labeled SABS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 256 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of SABS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SABS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.